Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

U.S. Department of Health and Human Services (HHS)National Institutes of Health

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

HomeImaging Inflammation in Alzheimer's Disease with 11C-ER176
Find more clinical trials

Imaging Inflammation in Alzheimer's Disease with 11C-ER176

Start: September 10, 2018
End: July 2022
Enrollment: 50

What Is This Study About?

Positron emission tomography (PET) imaging is a type of brain scanning method that allows researchers to use radioactive tracers to measure small molecules in the brain. This study will test the ability of the radioactive tracer 11C-ER176 to stick to parts of the brain where there is inflammation. Participants will undergo PET scanning and blood sampling to measure 11C-ER176. Another type of dye, florbetaben, which has been approved by the U.S. Food and Drug Administration to help diagnose Alzheimer's disease, will also be used.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: N/A

Must have:

  • Meet criteria for either a) amnestic mild cognitive impairment (MCI) or Alzheimer's disease, or b) have no cognitive impairment
  • If unable to provide informed consent, must have surrogate decision maker and be able to verbally assent to study procedures
  • Fluent in written and spoken English
  • Able to participate in all scheduled evaluations and to complete all required tests and procedures
  • Must be considered likely to comply with study protocol and have a high probability of completing the study

Must NOT have:

  • Past or present history of certain brain disorders other than MCI or Alzheimer's disease
  • Certain significant medical conditions that make study procedures unsafe, including uncontrolled epilepsy and multiple serious injuries
  • Inability to undergo magnetic resonance imaging, including metal implants, morbid obesity, and claustrophobia
  • Exposure to research-related radiation in the past year that would exceed allowable limits
  • Participation in the last year in a clinical trial for a disease-modifying Alzheimer's drug
  • Inability to have a catheter in the vein for the injection of the tracer
  • Inability to have blood drawn from veins
  • Taking anticoagulant medication (e.g., warfarin)

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: William Charles Kreisl

Source: ClinicalTrials.gov ID: NCT03744312

 

alzheimers.gov

An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health